1-nitro-4-piperidinonaphthalene | 34599-45-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-nitro-4-piperidinonaphthalene
• 英文别名: 1-(4-nitro-naphthalen-1-yl)-piperidine；1-(4-nitro-[1]naphthyl)-piperidine；1-(4-Nitro-[1]naphthyl)-piperidin；1-(4-nitronaphthalen-1-yl)piperidine；4-Piperidino-1-nitro-naphthalin；1-Nitro-4-piperidinonaphthalin；1-(4-Nitro-1-naphthyl)piperidine
• CAS: 34599-45-6
• 化学式: C₁₅H₁₆N₂O₂
• 分子量: 256.304
• InChiKey: GXNKHDGGLAANRD-UHFFFAOYSA-N

物化性质

• 熔点：
  70-71 °C(Solv: ligroine (8032-32-4))
• 沸点：
  449.8±28.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-nitro-4-piperidinonaphthalene 在 盐酸 、 tin 作用下， 生成 4-piperidino-[1]naphthylamine
  参考文献：
  名称：

  166.芳族化合物的阳离子型反应性。第一部分

  摘要：

  DOI：

  10.1039/jr9320001254
• 作为产物：
  描述：

  1-氨基-4-硝基萘 生成 1-nitro-4-piperidinonaphthalene
  参考文献：
  名称：

  Franzen; Helwert, Chemische Berichte, 1920, vol. 53, p. 320

  摘要：

  DOI：

文献信息

• NOVEL PHARMACEUTICAL
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1987827A1

  公开（公告）日：2008-11-05

  A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X1 represents an optionally substituted carbon atom, X2 represents an optionally substituted carbon atom, an oxygen atom and the like, W1 represents a nitrogen atom and the like, Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R3' represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R5' represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R1 represents an electron-withdrawing group, and the formula - - - represents a single bond or a double bond, or a salt thereof or a prodrug thereof.

  一种组合物，包含一种组分，该组分的结构式如下：其中，环A代表一个可选取代的5-至8环，环B代表一个可选进一步取代的4-至10环，环C代表一个可选进一步取代的苯环，X1代表一个可选取代的碳原子，X2代表一个可选取代的碳原子、氧原子等，W1代表一个氮原子等，Y11代表一个由式CR2R3'（其中，R2代表氢原子、氰基、硝基等，R3'分别代表键、氢原子、氰基、硝基等）表示的基团，Y21代表一个由式CR4R5'（其中，R4代表氢原子、氰基、硝基等，R5'分别代表键、氢原子、氰基、硝基等）表示的基团等，R1代表一个电子吸引基团，而式- - -表示单键或双键，或其盐或前药。
• Androgen receptor modulators and methods of treating disease using the same
  申请人：Schlienger Nathalie

  公开号：US20070004679A1

  公开（公告）日：2007-01-04

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文公开了一种公式（I）的双环芳基化合物，其选择性调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及包括向需要治疗的患者给予公式（I）化合物的治疗疾病的方法。
• Androgen receptor modulators and method of treating disease using the same
  申请人：Schlienger Nathalie

  公开号：US20060014739A1

  公开（公告）日：2006-01-19

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文公开了式(I)的双环芳基化合物，其选择性调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及通过向需要治疗的患者施用式(I)化合物的方法治疗疾病。
• Novel Pharmaceutical
  申请人：Yamaoka Masuo

  公开号：US20090042857A1

  公开（公告）日：2009-02-12

  A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X 1 represents an optionally substituted carbon atom, X 2 represents an optionally substituted carbon atom, an oxygen atom and the like, W 1 represents a nitrogen atom and the like, Y 11 represents a group represented by the formula CR 2 R 3′ (wherein R 2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R 3′ represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y 21 represents a group represented by the formula CR 4 R 5′ (wherein R 4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R 5′ represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R 1 represents an electron-withdrawing group, and the formula represents a single bond or a double bond, or a salt thereof or a prodrug thereof.

  一种组合物的组成式，该组合物是一种组织选择性的雄激素受体调节剂，其中环A代表可选取代的5-至8-环，环B代表可选取代的4-至10-环，环C代表可选取代的苯环，X1代表可选取代的碳原子，X2代表可选取代的碳原子、氧原子等，W1代表氮原子等，Y11代表由式CR2R3'（其中R2代表氢原子、氰基、硝基等，R3'代表键、氢原子、氰基、硝基等，分别）表示的基团，Y21代表由式CR4R5'（其中R4代表氢原子、氰基、硝基等，R5'代表键、氢原子、氰基、硝基等，分别）表示的基团等，R1代表电子吸引基团，式表示单键或双键，或其盐或前药。
• ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME
  申请人：Schlienger Nathalie

  公开号：US20080009489A1

  公开（公告）日：2008-01-10

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文披露了公式(I)的双环芳基化合物，其有选择性地调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及治疗疾病的方法，包括向需要该化合物的患者施用公式(I)的化合物。